during pre-transplantation work-up is crucial from a quality-adjusted life expectancy perspective. The cumulative time on HD can be considered a more important driver of the differences in QALYs between the 4 strategies than the higher rate of metastatic progression associated with AS. Future decision-analytic research should mainly focus on the investigation of the 2 favored strategies B & D and also incorporate a cost perspective.
INTRODUCTION AND OBJECTIVES: Robot-assisted surgery of the inferior vena cava (IVC) has been increasingly utilized as a minimally invasive alternative to a traditionally open approach. This surgical technique has been primarily described for renal masses with tumor thrombus, however similar principles can be applied to other less commonly performed procedures such as removal of IVC filters (IVCF) and left renal vein transposition (RVT) for nut cracker syndrome. We aim to describe our operative experience with robot assisted surgery of the IVC with regard to feasibility, safety, and preservation of caval diameter.
METHODS: A retrospective review was performed on surgeries completed within the last decade at Mayo Clinic Arizona. All patients had complete mobilization of the IVC with division of lumbar veins when required, allowing for proximal and distal control prior to cavotomy. Patient characteristics, operative reports, and follow up visits were analyzed. Preoperative and postoperative imaging was independently reviewed by a single radiologist. Complications were analyzed using the Clavien-Dindo grading system. RESULTS: Twenty-seven patients were identified to have undergone robot-assisted surgery of the IVC from January 2008-May 2018. 21 patients underwent surgery for urologic malignancy, 4 for IVCF removal, and 3 for RVT. Median age was 62 years. Median operative time and estimated blood loss was 323 minutes and 400mL, respectively. Median length of stay was 3 nights. All cavotomies were closed primarily except one, which required ligation due to chronic thrombus. 22 (82%) patients received some form of anticoagulation/antiplatelet therapy on discharge, at a median duration of 14 days. There were five complications, ranging from Clavien-Dindo grade II-IIIa. No patients required return to the operating room and there were no perioperative mortalities. Two patients experienced thromboembolic complications. Postoperative abdominal imaging was completed in 12 (44%) patients. In all imaging studies, the vena cava was patent, and no patients had symptoms of venous congestion. The median (interquartile range) percent reduction in IVC diameter was 41% (29-62%) on axial diameter, and 63% (50-72%) on sagittal diameter.
CONCLUSIONS: Robot assisted surgery offers the advantage of minimally invasive surgery with the additional ability to apply open surgical principles. Patients experienced minimal perioperative complications with preservation of the IVC diameter.
Source of Funding: none

PD54-06 TREATMENT OF RENAL ARTERY IN-STENT RESTENOSIS: A BAYESIAN NETWORK META-ANALYSIS
Jeffrey Sack*, Sarasota, FL; Jayme Sack, Saddle River, NJ; Hari Tunuguntla, Piscataway, NJ INTRODUCTION AND OBJECTIVES: The optimal treatment for renal artery in-stent restenosis (RAISR) is unknown. To determine the optimal treatment for RAISR, we conducted a Bayesian network metaanalysis comparing percutaneous balloon angioplasty (PTA), bare metal stent (BMS), drug eluding stent (DES), and cutting balloon angioplasty (CB METHODS: We searched MEDLINE, Cochrane and EMBASE libraries for all studies using pre-specified criteria of endovascular treatments for RAISR without restriction on language between January 1980 to April 2018. We excluded patients who had renal transplant renal artery stenosis. A Bayesian network meta-analysis was performed using WinBUGS (v1.4.3) comparing PTA vs BMS vs DES vs CB using both a fixed and random effect model using non-informative priors. PTA was considered the reference treatment and odds ratios (OR) for 12-month restenosis were calculated for all comparisons along with 95% confidence intervals (CI). There was insufficient data to include covered stents, drug coated balloons and brachytherapy. We calculated the surface under the cumulative ranking (SUCRA) a simple numerical summary of the probabilities. SUCRA is 100% when a treatment is certain to be the best and 0% when the treatment is certain to be the worst. Bias was assessed using heterogeneity plots and the Cochrane tool. RESULTS: We included 13 studies involving a total of 943 patients. (mean age 65.1 years, 60% male). DES was the most effective treatment for RAISR with an OR[0.26 [95% CI, (0.02-3.04)], compared with PTA and a SUCRA of 81% followed by CB [OR 0.28, (0.06-1.00), SUCRA[70%] and BMS [OR 0.62, SUCRA[37%] . PTA scored the lowest SUCRA of 12%, consistent with the least effect treatment of those compared.
CONCLUSIONS: Based on these data, treatment of RAISR with DES appears to be most favored, followed by CB, BMS and then PTA. The lack of randomized controlled trials and the small data sets of the included studies limits our findings.
